ASRA welcomes support from its corporate partners. There are several ways for corporations to be recognized for their support of the organization and its goals. Together, we can make a difference for patients and the education of physicians who serve them. Acceptance of any form of corporate support is independent of ASRA's policies and programming, and does not constitute endorsement of any company or product.
or contact Angela Stengel, Executive Director
The purpose of promoting ASRA Corporate Partnership is to develop and sustain a mutually beneficial relationship between ASRA and members of industry who have a vested interest in the area of regional anesthesia and pain management. The monies gained by ASRA from the Corporate Partnership Program provide an additional source of revenue for the Society each year, which is applied toward educational and research endeavors ASRA wishes to provide for its physician members.
Your best opportunity to partner with ASRA is through the Corporate Partnership Program. By becoming an ASRA Corporate Partner, you will help advance the quality of care provided by ASRA physician member by contributing your voice and support to members' efforts in research, education, treatment, and advocacy. Learn more about the many benefits of becoming an ASRA Corporate Partner.
Thank You to ASRA's Corporate Partners:
Avanos is a medical technology company focused on delivering clinically superior breakthrough medical device solutions to improve patients’ quality of life. Avanos is committed to addressing some of today’s most important healthcare needs, such as reducing the use of opioids while helping patients move from surgery to recovery. With a relentless focus on advancing change in the medical devices industry to address unmet medical needs and improve patients’ quality of life, Avanos provides pioneering pain management and chronic care therapies and solutions.
FUJIFILM SonoSite, Inc., the world leader in bedside and point-of-care ultrasound (POCUS), delivers solutions that meet the imaging needs of the medical community. Headquartered near Seattle, the company is represented by a global distribution network in over 100 countries. As a recognized market leader, SonoSite continues to earn worldwide recognition for its innovative product line, educational programs, and advocacy for a broader understanding of ultrasound’s many benefits.
At Medtronic, we're committed to Innovating for Life by pushing the boundaries of medical technology and changing the way the world treats chronic disease. Medtronic Neuromodulation provides implantable neurostimulation and drug delivery devices to treat intractable pain, movement and neurological disorders. We offer the largest range of Neuromodulation products with exceptional technical services and patient support.
Pajunk® Medical is a leading manufacturer in regional anesthesia, neurology, pain management, minimally invasive surgery, and biopsy. Pajunk was founded in 1965 by two brothers, Horst and Heinrich Pajunk, who had a vision to bring high quality German engineering to the manufacturing of medical devices. Throughout the years Pajunk became well-known for working closely with clinicians on new innovations, further strengthening the efficacy of their product portfolio. Today, the tradition continues as the next generation of Pajunk’s are dedicated to expanding their innovations to existing and new markets, including interventional and chronic pain.
Pajunk is headquartered in Geisingen, Germany, with subsidiaries in Atlanta (USA) and Newcastle (UK). In the US, Pajunk specializes in regional anesthesia and pain management by offering market-leading solutions for peripheral and continuous nerve blocks, neuraxial procedures and diagnostics, and interventional pain. Learn more at www.pajunkusa.com or www.pajunk.com.
RedHill Biopharma is a specially biopharmaceutical company that promotes Movantik and other gastrointestinal drugs in the U.S. Movantik® is a proprietary, once-daily, oral PAMORA (peripherally acting mu-opioid receptor antagonist) approved for the treatment of OIC (opioid-induced constipation) in adult patients with chronic, non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. Movantik® is the first oral PAMORA approved in the U.S. for the treatment of OIC and is recommended in the American Gastroenterological Association (AGA) and the National Comprehensive Cancer Network (NCCN) guidelines.
Information on advertising and sponsorship can be found here.